Table 3.
Risk Factors | Overall Survival (PFS) | |||
---|---|---|---|---|
Univariate Analysis | Multivariate Analysis | |||
OR (95% CI) | P Value | OR (95% CI) | P Value | |
Age (>51.5 or ≤51.5 years) | 1.046 (0.700-1.562) | 0.630 | – | – |
Tumor size (> 4 or ≤ 4), cm | 1.561 (1.039-2.346) | 0.032a | 1.424 (0.913-2.222) | .119 |
Lymphonodus metastasis (have or none) | 1.104 (0.738-1.652) | 0.630 | – | – |
FIGO stage (II or I) | 1.615 (1.076-2.424) | 0.021a | 1.709 (1.114-2.621) | .121 |
Differentiation (moderately, poorly or highly) | 1.720 (1.142-2.592) | 0.009b | 1.682 (1.048-2.700) | .014a |
Pretreatment CRP level (>2.62 or ≤2.62), mg/L | 1.721 (1.148-2.581) | 0.009b | 1.682 (1.048-2.700) | .031a |
Pretreatment ALB level (≤42.1 or > 42.1), g/L | 0.860 (0.575-1.287) | 0.463 | – | – |
Pretreatment GLB level (>27.7 or ≤27.7), g/L | 0.919 (0.615-1.373) | 0.680 | – | – |
Pretreatment LDH level (>193 or ≤193), U/L | 1.656 (1.107-2.478) | 0.014a | 1.759 (1.155-2.678) | .009b |
Pretreatment AGR level (>1.47 or ≤1.47) | 1.077 (0.721-1.609) | 0.716 | – | – |
Post/preradiotherapy CRP ratio (>1 or ≤1) | 1.773 (1.179-2.665) | 0.006b | 1.410 (0.875-2.272) | .158 |
Post/preradiotherapy ALB ratio (>1 or ≤1) | 0.835 (0.559-1.247) | 0.379 | – | – |
Post/preradiotherapy GLB ratio (>1 or ≤1) | 0.516 (0.585-1.309) | 0.516 | ||
Post/preradiotherapy LDH ratio (>1 or ≤1) | 1.839 (1.204-2.810) | 0.005b | 1.514 (0.948-2.418) | .080 |
Post/preradiotherapy AGR ratio (>1 or ≤1) | 0.748 (0.500-1.121) | 0.159 | – | – |
Post/pretreatment CRP ratio (>1 or ≤1) | 1.576 (1.050-2.367) | 0.028a | 1.423 (0.866-2.338) | .164 |
Post/pretreatment ALB ratio (>1 or ≤1) | 0.978 (0.657-1.482) | 0.950 | – | – |
Post/pretreatment GLB ratio (>1 or ≤1) | 1.055 (0.706-1.578) | 0.793 | ||
Post/pretreatment LDH ratio (>1 or ≤1) | 1.032 (0.689-1.261) | 1.544 | – | – |
Post/pretreatment AGR ratio (>1 or ≤1) | 0.805 (0.536-1.207) | 0.293 | – | – |
Abbreviation: AGR, albumin-to-globulin ratio; ALB, albumin; CRP, C-reactive protein; CI, confidence interval; FIGO, Federation of Gynecology and Obstetrics; GLB, globulin; LDH, lactate dehydrogenase; OR, odds ratio; PFS, progression-free survival.
aP < .05.
bP < .01.